SASCIA

About this trial

This study is a phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA

Patient Profile

Primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment

Where’s this trial being run?

Beaumont Hospital, Cork University Hospital, St James’s Hospital, St Vincents University Hospital, University Hospital Limerick, University Hospital Waterford, and Mater Misericordiae University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: SASCIA
Number: 20-24
Full Title:

Phase III postneoadjuvant study evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in primary HER2- negative breast cancer patients with high relapse risk after standard neoadjuvant treatment – SASCIA

Principal Investigator: Prof. Patrick Morris
Type: Collaborative
Sponsor:

GBG

Recruitment Started: Global: 28-Oct-2020
Ireland: 08-Dec-2021
Global Recruitment Target: Approx 1200 patients
Ireland Recruitment Target: Approx 40 patients